Short hydration in chemotherapy containing cisplatin (≥75 mg/m2) for patients with lung cancer: A prospective study

Japanese Journal of Clinical Oncology

Volumn 43, Issue 11, 2013, Pages 1105-1109

  Horinouchi, Hidehito ^a   Kubota, Kaoru ^a   Itani, Hidetoshi ^a   Taniyama, Tomoko Katsui ^a   Nakamichi, Shinji ^a   Wakui, Hiroshi ^a   Kanda, Shintaro ^a   Nokihara, Hiroshi ^a   Yamamoto, Noboru ^a   Sekine, Ikuo ^a   Tamura, Tomohide ^a  

^a NATIONAL CANCER CENTER HOSPITAL   (Japan)

Author keywords

Cisplatin; Lung cancer; Magnesium supplementation; Renal toxicity; Short hydration

Indexed keywords

AMINOTRANSFERASE; CISPLATIN; CREATININE; DOCETAXEL; ETOPOSIDE; GEMCITABINE; MAGNESIUM SULFATE; MANNITOL; NAVELBINE; PEMETREXED; POTASSIUM CHLORIDE;

ADULT; AGED; ALOPECIA; AMINOTRANSFERASE BLOOD LEVEL; ANOREXIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CHEMORADIOTHERAPY; CLINICAL ARTICLE; CONSTIPATION; CREATININE BLOOD LEVEL; DIARRHEA; DIURESIS; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FEVER; GASTROINTESTINAL TOXICITY; HUMAN; HYDRATION; KIDNEY DYSFUNCTION; LUNG CANCER; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA; OUTCOME ASSESSMENT; PHASE 2 CLINICAL TRIAL; PROSPECTIVE STUDY; SIDE EFFECT; TREATMENT DURATION; VOMITING; WEIGHT REDUCTION;

CISPLATIN; LUNG CANCER; MAGNESIUM SUPPLEMENTATION; RENAL TOXICITY; SHORT HYDRATION;

ADENOCARCINOMA; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOLOGICAL MARKERS; CARCINOMA, SMALL CELL; CARCINOMA, SQUAMOUS CELL; CHEMOTHERAPY, ADJUVANT; CISPLATIN; CREATININE; FEMALE; FLUID THERAPY; GASTROINTESTINAL TRACT; GLUTAMATES; GUANINE; HUMANS; JAPAN; KIDNEY; LUNG NEOPLASMS; MAGNESIUM; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RADIOTHERAPY, ADJUVANT; RENAL INSUFFICIENCY; TREATMENT OUTCOME;

EID: 84887115956     PISSN: 03682811     EISSN: 14653621     Source Type: Journal    
DOI: 10.1093/jjco/hyt122     Document Type: Article

References (23)

1. Furuse K, Fukuoka M, Kawahara M, et al. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer. J Clin Oncol 1999;17:2692-9.
2. Winton T, Livingston R, Johnson D, et al. Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer. N Engl J Med 2005;352:2589-97.
3. Scagliotti GV, Parikh P, von Pawel J, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 2008;26:3543-51.
4. Ardizzoni A, Boni L, Tiseo M, et al. Cisplatin- versus carboplatin-based chemotherapy in first-line treatment of advanced non-small-cell lung cancer: an individual patient data meta-analysis. J Natl Cancer Inst 2007;99:847-57.
5. Yamada K, Yoshida T, Zaizen Y, et al. Clinical practice in management of hydration for lung cancer patients receiving cisplatin-based chemotherapy in Japan: a questionnaire survey. Jpn J Clin Oncol 2011;41:1308-11.
6. Sekine I, Kubota K, Tamura Y, et al. Innovator and generic cisplatin formulations: comparison of renal toxicity. Cancer Sci 2011;102:162-5.
7. Cvitkovic E, Spaulding J, Bethune V, et al. Improvement of cisdichlorodiammineplatinum (NSC 119875): therapeutic index in an animal model. Cancer 1977;39:1357-61.
8. Hayes DM, Cvitkovic E, Golbey RB, et al. High dose cis-platinum diammine dichloride: amelioration of renal toxicity by mannitol diuresis. Cancer 1977;39:1372-81.
9. Willox JC, McAllister EJ, Sangster G, Kaye SB. Effects of magnesium supplementation in testicular cancer patients receiving cis-platin: a randomised trial. Br J Cancer 1986;54:19-23.
10. Bodnar L, Wcislo G, Gasowska-Bodnar A, et al. Renal protection with magnesium subcarbonate and magnesium sulphate in patients with epithelial ovarian cancer after cisplatin and paclitaxel chemotherapy: a randomised phase II study. Eur J Cancer 2008;44:2608-14.
11. Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982; 5:649-55.
12. Simon R. Optimal two-stage designs for phase II clinical trials. Control Clin Trials 1989;10:1-10.
13. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009;45:228-47.
14. Dobyan DC, Levi J, Jacobs C, et al. Mechanism of cis-platinum nephrotoxicity: II. Morphologic observations. J Pharmacol Exp Ther 1980;213:551-6.
15. Pera MF, Jr, Zook BC, Harder HC. Effects of mannitol or furosemide diuresis on the nephrotoxicity and physiological disposition of cis-dichlorodiammineplatinum-(II) in rats. Cancer Res 1979;39: 1269-78.
16. Ostrow S, Egorin MJ, Hahn D, et al. High-dose cisplatin therapy using mannitol versus furosemide diuresis: comparative pharmacokinetics and toxicity. Cancer Treat Rep 1981;65:73-8.
17. Santoso JT, Lucci JA, 3rd, Coleman RL, et al. Saline, mannitol, and furosemide hydration in acute cisplatin nephrotoxicity: a randomized trial. Cancer Chemother Pharmacol 2003;52:13-8.
18. Sobrero A, Guglielmi A, Aschele C, Rosso R. Current strategies to reduce cisplatin toxicity. J Chemother 1990;2:3-7.
19. Hodgkinson E, Neville-Webbe HL, Coleman RE. Magnesium depletion in patients receiving cisplatin-based chemotherapy. Clin Oncol (R Coll Radiol) 2006;18:710-8.
20. Tiseo M, Martelli O, Mancuso A, et al. Short hydration regimen and nephrotoxicity of intermediate to high-dose cisplatin-based chemotherapy for outpatient treatment in lung cancer and mesothelioma. Tumori 2007;93:138-44.
21. Stewart DJ, Dulberg CS, Mikhael NZ, et al. Association of cisplatin nephrotoxicity with patient characteristics and cisplatin administration methods. Cancer Chemother Pharmacol 1997;40:293-308.
22. Vogl SE, Zaravinos T, Kaplan BH. Toxicity of cisdiamminedichloroplatinum II given in a two-hour outpatient regimen of diuresis and hydration. Cancer 1980;45:11-5.
23. Brock J, Alberts DS. Safe, rapid administration of cisplatin in the outpatient clinic. Cancer Treat Rep 1986;70:1409-14.